Is BPC-157 Legal in Colorado? How to Access It Legally

Where BPC-157 stands federally

BPC-157 is a synthetic 15-amino-acid peptide made as a free base or an acetate salt, which FDA treats as two different bulk substances [1]. It is not approved in the United States, has no US Pharmacopeia or National Formulary monograph, and FDA's July 2026 review found no approved product containing it in any country it searched [1].

In compounding, it is in none of the three categories on FDA's list of nominated bulk substances for state-licensed pharmacies and physicians (updated May 14, 2026), so FDA's category 1 enforcement discretion does not cover it [2]. It is also not on FDA's list for outsourcing facilities (updated March 21, 2025) [3].

Category 2, the 2026 advisory vote, and the draft HHS policy

BPC-157 was in category 2 (bulk substances FDA says may present significant safety risks) from September 2023 until April 22, 2026, when the nominators withdrew and it moved to a 'nominated but withdrawn' table. Removal was not a finding of safety [6]. FDA's stated concerns remain on that page, including possible immunogenicity for certain routes of administration and its statement that it 'lacks sufficient information to know whether the drug would cause harm when administered to humans' [6].

On July 23, 2026 FDA's Pharmacy Compounding Advisory Committee voted in favor of adding BPC-157 to the pharmacy bulks list, against FDA staff's recommendation; news reports give the vote as 8 to 6 with 1 abstention. The vote is advice only, and BPC-157 is not on the list [7][5]. FDA's reviewers had proposed against listing, citing poor chemical characterization, limited safety and immunogenicity information, and insufficient evidence that it works for ulcerative colitis, the use FDA evaluated [1].

On October 28, 2026 HHS filed notice of a draft policy stating it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with BPC-157 while FDA's list is developed through rulemaking, if conditions are met [4][5]. Conditions include the acetate form; subcutaneous, intramuscular, oral or topical routes, with nasal, rectal and intravenous not listed; a single active ingredient; bulk substance from an FDA-registered manufacturer with a certificate of analysis meeting a peptide testing standard; a patient-specific prescription; and the label 'This is a compounded drug product. Not for resale.' [5] The notice says the policy 'does not establish any rights for any person and is not binding on HHS or the public', and it names state-licensed pharmacies, federal facilities and licensed physicians, not outsourcing facilities [4][5].

What this means in Colorado

The federal limits above apply in Colorado. State pharmacy and medical licensing rules also apply to any Colorado pharmacy or physician, and this page does not cover them.

Products sold online as 'for research purposes only' are not FDA-approved drugs. FDA has identified BPC-157 products sold as capsules, injections, oral sprays and nasal sprays, including products carrying that label [1].

Athletes, and how thin the human evidence is

WADA names BPC-157 in S0 (non-approved substances) and prohibits it at all times, in and out of competition; the 2026 List has been in force since January 1, 2026 [8].

FDA found five small human studies and concluded there is 'insufficient clinical safety information to characterize the safety profile' of BPC-157 [1]. A 2026 systematic review found 3 studies in 30 patients, all of poor methodological quality, with certainty of evidence rated very low [9].